DLB Reddit Mentions | ChartExchange

Os of 6/26/2026 CGTX is included in Russell3000 ...The standard practice across biotech and small cap companies is to issue a Russell press release immediately — because it's considered material news for shareholders, it's a legitimate positive development, and frankly most small cap management teams take every opportunity to generate positive press coverage.
Companies like D-Wave Quantum, i-80 Gold, Security National Financial — none of these are companies with sophisticated investor relations philosophies. They all issued press releases immediately. It's almost reflexive at the small cap level.
The Case For Your Theory — Management Conservatism
There are actually some signals in CGTX's history that support the idea that Ricciardi runs a deliberately conservative investor relations program:
Signal 1 — The June 24 FDA minutes framing:
When the FDA written minutes dropped June 24 — the most important milestone in the company's history — the press release was measured and precise. No hyperbole. No "transformative" language. Just the facts of what the FDA confirmed. That's unusual restraint for a small cap biotech that could have generated enormous retail excitement with more aggressive language.
Signal 2 — The 89% figure handling:
The 89% hallucination and delusion slowing figure has been mentioned in one press release — but CGTX has never issued a dedicated press release specifically spotlighting that number with full statistical context. They're holding it for AAIC London. A company trying to pump its stock would have issued three separate press releases about that number by now.
Signal 3 — The Expanded Access Program:
The Expanded Access Program was extended in February 2026 — allowing real-world DLB patients continued access to zervimesine. Most companies would have issued a press release framing this as evidence that patients and physicians are so convinced of the drug's benefit they're requesting continued access. CGTX disclosed it quietly in a routine update.
Signal 4 — No ATM share sales at the bottom:
When the stock was at $0.29 — a desperate cash position for most small cap biotechs — CGTX did not aggressively use its $75 million ATM offering to sell shares at catastrophically dilutive prices. They preserved shareholder value even under severe financial pressure.
Signal 5 — Insider buying not publicized:
When the CFO bought 10,000 shares on earnings day and the CEO bought 9,175 shares in April — neither purchase was accompanied by any press release drawing attention to it. They filed the Form 4 as required and said nothing else. A company trying to inflate its stock would have issued a press release saying "our executives are so confident they're buying shares with their own money."
The Counter-Argument — Why It's Probably Not the Primary Reason
Here's the uncomfortable alternative explanation: if CGTX was never previously in the Russell 3000, they may simply have never had the opportunity to issue such a press release before. The stock at $0.29 was disqualified on both price and market cap grounds. There was nothing to announce.
And if June 2026 is genuinely their first inclusion — they may have missed the announcement window. The preliminary Russell list was posted in late May 2026. CGTX was simultaneously managing:
The May 20 FDA Type B meeting
The June 24 written minutes press release preparation
The June 16 patent announcement
The June 17 annual shareholder meeting
AAIC abstract preparation for July
A small investor relations team managing that many simultaneous material events may simply have deprioritized the Russell announcement — not out of philosophical conservatism but out of bandwidth constraints.
The Most Interesting Interpretation — Deliberate Sequencing
Here's a third possibility that combines both explanations and is actually the most strategically sophisticated reading:
Lisa Ricciardi may have deliberately chosen not to issue a Russell press release now — in order to bundle it with the AAIC London announcement in two weeks.
Think about what that press release could look like on July 12-15:
"Cognition Therapeutics presents DLB psychosis data at AAIC London showing 89% slowing of hallucinations and delusions. The company also announces its first-ever inclusion in the Russell 3000 Microcap Index, expanding institutional investor eligibility as the company prepares for its Phase 3 DLB registrational trial."
That's a much more powerful press release than either announcement made separately. The Russell inclusion provides institutional credibility context for the scientific data. The scientific data provides substance for what would otherwise be a routine index announcement. Together they create a narrative of a company arriving at institutional maturity at precisely the moment its most important clinical data is being presented to the world's leading dementia researchers.
If that's the strategy — it's genuinely sophisticated investor relations management. Not overpromising. Not artificially inflating. Just sequencing legitimate positive developments for maximum coherent narrative impact.